

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

MEDAC PHARMA, INC. and MEDAC)
GESELLSCHAFT FÜR KLINISCHE)
SPEZIALPRÄPARATE MBH,)

Plaintiffs,)

v.)

ANTARES PHARMA, INC., LEO PHARMA A/S,)
and LEO PHARMA INC.,)

Defendants.)

No. 1:14-cv-01498-JBS-KMW

Motion Date: August 4, 2014

**DECLARATION OF LILLIAN M. ROBINSON IN SUPPORT OF MOTION TO STAY
LITIGATION PENDING OUTCOME OF *INTER PARTES* REVIEW**

I, Lillian M. Robinson, declare as follows:

1. I am an attorney licensed to practice in Georgia and the District of Columbia, and am an associate with Finnegan, Henderson, Farabow, Garrett & Dunner LLP, counsel for Defendants Antares Pharma, Inc. (“Antares”), Leo Pharma A/S (“Leo Pharma”), and Leo Pharma Inc. (“Leo Inc.”) (all collectively “Antares”). I have been admitted pro hac vice in this matter, and I submit this Declaration in support of Defendants’ Motion to Stay Litigation Pending Outcome of *Inter Partes* Review filed herewith. The matters stated herein are based upon my personal knowledge, and if called as a witness, I would testify as to the following statements.

2. Attached hereto is a true and correct copy of the following exhibits:

Exhibit 1: OtrexupTM Label.

Exhibit 2: Nov. 14, 2013, Antares Press Release.

Exhibit 3: Jan. 27, 2014, Medac Press Release.

Exhibit 4: U.S. Patent 8,664,231.

Exhibit 5: July 1, 2014, Petition for IPR of ’231 Patent (IPR2014-01091).

Exhibit 6: *Corning Gilbert Inc. v. PPC Broadband, Inc.*, IPR2013-00343, Paper 16 (P.T.A.B. Dec. 23, 2013).

Exhibit 7: *Mobotix Corp. v. e-Watch, Inc.*, IPR2013-00499, Paper 17 (P.T.A.B. Apr. 9, 2014).

Exhibit 8: PTAB AIA Progress Statistics, dated July 2, 2014.

Exhibit 9: EP Pat. No. 2046332.

I declare under the penalty of perjury under the laws of the United States that the foregoing is true and correct. Executed this 11th day of July, 2014 in Washington, D.C.

DATE: July 11, 2014

By: /s/ Lillian M. Robinson
Lillian M. Robinson (pro hac vice)
Attorney for Defendants